Marksans Pharma Limited Bombay S.E.

Equities

MARKSANS

INE750C01026

Pharmaceuticals

Delayed Bombay S.E. 06:00:51 2024-03-28 am EDT 5-day change 1st Jan Change
151.6 INR +0.46% Intraday chart for Marksans Pharma Limited +4.88% -5.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Marksans Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Marksans Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Marksans Pharma Arm Gets UK Regulator's Approval to Market Cyanocobalamin Tablets MT
Marksans Pharma Undergoes Successful Inspection from German Health Authorities MT
CARE Affirms A+ Rating on Marksans Pharma's Long-term Bank Financing; Outlook Stable MT
Marksans Pharma Gets US FDA Nod for Esomeprazole Magnesium Delayed-Release Capsules MT
Marksans Pharma Limited Announces US FDA Approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg CI
Marksans Pharma Limited Approves Payment of Dividend CI
Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director CI
Marksans Pharma Gets US FDA's Final Approval for Generic Cough Medicine MT
Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets CI
Marksans Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23 CI
Marksans Pharma's Goa Plant Gets Two Observations from US FDA MT
Marksans Pharma Gets US FDA Nod for Pain Relief Drug MT
Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg CI
Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023 CI
Marksans Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Marksans Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Marksans Pharma Completes Acquisition of Manufacturing Site in Goa, India MT
Marksans Pharma Limited acquired Bulk Pharmaceutical Business of Tevapharm India Private Limited. CI
Marksans Pharma Gets US FDA's Final Approval for Generic Stomach Ulcers Drug MT
Marksans Pharma Limited Announces US FDA Approval for Famotidine Tablets USP, 10 Mg and 20 Mg CI
Transcript : Marksans Pharma Limited, Q3 2023 Earnings Call, Feb 14, 2023
Marksans Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Chart Marksans Pharma Limited
More charts
Marksans Pharma Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The Company produces goods across various therapeutic areas, such as pain management, cough and cold, cardiovascular and central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic, among others. The Company operates four manufacturing facilities across India, the United Kingdom and the United States. The Company manufactures oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
151.9
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Marksans Pharma Limited
  4. Stock Marksans Pharma Limited - Bombay S.E.
  5. News Marksans Pharma Limited
  6. Marksans Pharma : Shareholders OK Issuance of Convertible Warrants Worth $490 Million to OrbiMed